Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
CJC-1295 + Ipamorelin Blend
This report covers the 10mg lot. Other sizes ship to our supplier batch specification.
3–7 days most of the EU · 8–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€13.99 · Same-day dispatch before 14:00 CET on weekdays · Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay — approve a SEPA transfer in your own bank via Paysera’s hosted page, or send a manual SEPA transfer using the IBAN we email you.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders placed before 14:00 CET on a weekday typically ship the same day.
Card payments are not currently offered. There is no card processor on this checkout.
Free shipping on orders over €200
Research-grade CJC-1295 + Ipamorelin Blend. ≥98% supplier batch specification; selected lots independently tested. Lyophilized powder in sealed glass vial. For laboratory research use only. Not for human consumption.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €68.49 | €68.49 | -- |
| 3+ | €65.07 | €195.20 | 5% off |
| 5+Most Popular | €61.64 | €308.21 | 10% off |
| 10+ | €58.22 | €582.17 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
When This Product May Not Suit Your Research
- ⚠If your research requires GMP-grade material for clinical applications — research-grade peptides are not intended for clinical use.
- ⚠If your lab lacks proper cold storage (-20°C freezer) — this peptide's stability may be compromised at higher temperatures.
- ⚠If your study protocol requires FDA-approved reference standards — contact USP or a certified reference material provider.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
This report covers the 10mg lot. Other sizes ship to our supplier batch specification.
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
About CJC-1295 + Ipamorelin Blend
Two receptors drive pituitary GH release: the GHRH receptor (activated by GHRH and its analogs) and the ghrelin receptor GHS-R1a (activated by ghrelin, ipamorelin, and the GHRP family). They work through separate intracellular pathways — cAMP for GHRH-R, calcium and PKC for GHS-R — and when both are activated simultaneously, GH output is larger than either pathway produces alone. This blend is that combination pre-mixed: CJC-1295 without DAC (Mod GRF 1-29) as the GHRH component, ipamorelin as the selective GHSR agonist. One vial, one reconstitution, co-administered.
Why the Combination Specifically
The selectivity of ipamorelin is what makes this pairing clean. GHRP-2 and GHRP-6 also activate GHS-R but raise cortisol and prolactin as side effects. Ipamorelin activates GHS-R with minimal effect on those axes. For research where the question is specifically about GH axis dynamics — without cortisol or prolactin elevation as confounding variables — ipamorelin is the right GHSR agonist for this combination.
The combination also preserves somatostatin sensitivity, meaning the feedback architecture of the GH axis stays intact. Pulses are larger, but the somatostatin brake still functions. This is different from exogenous GH administration, which bypasses pituitary regulation entirely. For GH secretagogue synergy, pulse amplitude and frequency analysis, or age-related somatopause research, the dual-receptor stimulation is the experimental foundation.
Specifications
| Blend | CJC-1295 without DAC + Ipamorelin |
|---|---|
| Purity | ≥98% (supplier batch spec) |
| Form | Lyophilized powder |
| Sizes | 10mg blend, 20mg blend |
Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.
Quality: Every product ships to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical, searchable by batch code at certapeptides.com/verify. EU-based QC under CERTALAB S.R.L.
Frequently Asked Questions
Why does combining CJC-1295 and ipamorelin produce more GH than either alone?
CJC-1295 (GHRH analog) and ipamorelin (GHSR agonist) activate different receptor systems on pituitary somatotrophs. GHRH-R signals through cAMP, GHS-R through calcium and PKC. Dual stimulation converges on GH release through independent pathways, producing larger pulses than either receptor system achieves alone. The two signals are additive, not redundant.
Why use ipamorelin rather than GHRP-2 or GHRP-6 in this combination?
Ipamorelin is selective for GHS-R1a on somatotrophs with minimal off-target hormonal effects. GHRP-2 and GHRP-6 also activate GHS-R but produce dose-dependent cortisol and prolactin elevation as secondary effects. For clean GH axis research where cortisol and prolactin are not intended variables, ipamorelin is the preferred GHSR agonist.
For research purposes only. Not for human consumption.
Specification Summary
About CJC-1295 + Ipamorelin Blend
Two receptors drive pituitary GH release: the GHRH receptor (activated by GHRH and its analogs) and the ghrelin receptor GHS-R1a (activated by ghrelin, ipamorelin, and the GHRP family). They work through separate intracellular pathways — cAMP for GHRH-R, calcium and PKC for GHS-R — and when both are activated simultaneously, GH output is larger than either pathway produces alone. This blend is that combination pre-mixed: CJC-1295 without DAC (Mod GRF 1-29) as the GHRH component, ipamorelin as the selective GHSR agonist. One vial, one reconstitution, co-administered.
Why the Combination Specifically
The selectivity of ipamorelin is what makes this pairing clean. GHRP-2 and GHRP-6 also activate GHS-R but raise cortisol and prolactin as side effects. Ipamorelin activates GHS-R with minimal effect on those axes. For research where the question is specifically about GH axis dynamics — without cortisol or prolactin elevation as confounding variables — ipamorelin is the right GHSR agonist for this combination.
The combination also preserves somatostatin sensitivity, meaning the feedback architecture of the GH axis stays intact. Pulses are larger, but the somatostatin brake still functions. This is different from exogenous GH administration, which bypasses pituitary regulation entirely. For GH secretagogue synergy, pulse amplitude and frequency analysis, or age-related somatopause research, the dual-receptor stimulation is the experimental foundation.
Specifications
| Blend | CJC-1295 without DAC + Ipamorelin |
|---|---|
| Purity | ≥98% (supplier batch spec) |
| Form | Lyophilized powder |
| Sizes | 10mg blend, 20mg blend |
Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.
Quality: Every product ships to a ≥98% supplier batch specification; selected lots are independently tested by Janoshik Analytical, searchable by batch code at certapeptides.com/verify. EU-based QC under CERTALAB S.R.L.
Frequently Asked Questions
Why does combining CJC-1295 and ipamorelin produce more GH than either alone?
CJC-1295 (GHRH analog) and ipamorelin (GHSR agonist) activate different receptor systems on pituitary somatotrophs. GHRH-R signals through cAMP, GHS-R through calcium and PKC. Dual stimulation converges on GH release through independent pathways, producing larger pulses than either receptor system achieves alone. The two signals are additive, not redundant.
Why use ipamorelin rather than GHRP-2 or GHRP-6 in this combination?
Ipamorelin is selective for GHS-R1a on somatotrophs with minimal off-target hormonal effects. GHRP-2 and GHRP-6 also activate GHS-R but produce dose-dependent cortisol and prolactin elevation as secondary effects. For clean GH axis research where cortisol and prolactin are not intended variables, ipamorelin is the preferred GHSR agonist.
For research purposes only. Not for human consumption.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
